Murtaza Ghulam, Siddiqui Adeel, Hussain Izhar
Department of Pharmacy, COMSATS University Islamabad, Lahore Campus, Pakistan.
Department of Pharmacy, Shaukat Khanum Memorial Cancer Hospital and Research Centre, Lahore, Pakistan.
Curr Protein Pept Sci. 2018;19(11):1079-1087. doi: 10.2174/1389203719666180709103020.
Cardiovascular (CV) diseases are caused by vascular dysfunction. The enhanced sensitivity to vasoconstrictors, reduced endothelium-derived vasodilators nitric oxide (NO) and prostacyclin (PGI2), and endothelium-derived hyperpolarization (EDH) indicate CV dysfunction. In recent years, recombinant human relaxin, known as serelaxin, has emerged as a new vasoactive drug that is useful in acute heart failure. First part of this review article encompasses the role of endogenous relaxin in CV homeostasis. Subsequently, vascular effects of serelaxin and the underlying modes of action in comparison to other vasodilators are discussed. Finally, the usefulness of treatment with serelaxin in vascular dysfunction in different CV diseases, particularly due to oxidative stress, is explained.
心血管（CV）疾病是由血管功能障碍引起的。对血管收缩剂的敏感性增强、内皮衍生的血管舒张剂一氧化氮（NO）和前列环素（PGI2）减少以及内皮衍生的超极化（EDH）表明存在心血管功能障碍。近年来，重组人松弛素（即希瑞适）已成为一种新型血管活性药物，可用于治疗急性心力衰竭。这篇综述文章的第一部分涵盖了内源性松弛素在心血管稳态中的作用。随后，将希瑞适的血管作用及其与其他血管舒张剂相比的潜在作用模式进行了讨论。最后，解释了希瑞适治疗不同心血管疾病中血管功能障碍的有效性，尤其是由于氧化应激导致的血管功能障碍。
